Phenobarbital Tapering Guidelines

Introduction to Tapering

The Centers for Disease Control and Prevention, as reported by MMWR Recommendations and Reports, recommends follow-up at least monthly during the taper, with more frequent contact during difficult phases 2

The American Academy of Family Physicians, as reported by Praxis Medical Insights, suggests that clinically significant withdrawal symptoms signal the need to further slow the taper rate or pause temporarily 1
The Centers for Disease Control and Prevention, as reported by MMWR Recommendations and Reports, advises monitoring specifically for withdrawal symptoms at each visit, including anxiety, tremor, muscle twitching, insomnia, sweating, tachycardia, nausea, vomiting, confusion, and seizures 2

The American College of Obstetricians and Gynecologists, as reported by Praxis Medical Insights, indicates that pregnant patients should be referred to a specialist due to the risk of spontaneous abortion and premature labor 1

The Centers for Disease Control and Prevention, as reported by MMWR Recommendations and Reports, suggests that for patients on phenobarbital for ≥1 year, plan for a taper lasting 6-12 months minimum, possibly longer 2
The American Academy of Family Physicians, as reported by Praxis Medical Insights, recommends that patient agreement and interest in tapering is a key component of success, using shared decision-making and explaining risks of continued use versus benefits of discontinuation 1

The American Psychological Association, as reported by Praxis Medical Insights, suggests that cognitive-behavioral therapy (CBT) during the taper significantly increases success rates and should be incorporated 1

The Centers for Disease Control and Prevention, as reported by MMWR Recommendations and Reports, advises that goals may vary, with some patients achieving complete discontinuation while others attain a reduced dosage at which functional benefits outweigh risks 2
The American Academy of Family Physicians, as reported by Praxis Medical Insights, recommends advising patients of increased overdose risk if they return to previously prescribed higher doses due to loss of tolerance 1